• Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S., Wali, B., Ellis, M., Davis-Gardner, M. E., Huerta, C., Bechnak, K., Bechnak, S., Lee, M., Litvack, M. B., Losada, C., Grifoni, A., Sette, A., Zarnitsyna, V. I., Rouphael, N., Suthar, M. S., Pulendran, B., 2023. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest, 133, e167955.

  • Devasundaram, S., Terpos, E., Rosati, M., Ntanasis-Stathopoulos, I., Bear, J., Burns, R., Skourti, S., Malandrakis, P., Trougakos, I. P., Dimopoulos, M. A., Pavlakis, G. N., Felber, B. K., 2023. XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1. Am J Hematol, 98, E123-E126.

  • Hoffmann, M., Arora, P., Nehlmeier, I., Kempf, A., Cossmann, A., Schulz, S. R., Morillas Ramos, G., Manthey, L. A., Jäck, H. M., Behrens, G. M. N., Pöhlmann, S., 2023. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5. Cell Mol Immunol, 20, 419-422.

  • Kaku, Y., Kosugi, Y., Uriu, K., Ito, J., Hinay, A. A., Jr, Kuramochi, J., Sadamasu, K., Yoshimura, K., Asakura, H., Nagashima, M., Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato, K., 2023. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5. Lancet Infect Dis, 23, e395-e396.

  • Ma, K. C., Shirk, P., Lambrou, A. S., Hassell, N., Zheng, X. Y., Payne, A. B., Ali, A. R., Batra, D., Caravas, J., Chau, R., Cook, P. W., Howard, D., Kovacs, N. A., Lacek, K. A., Lee, J. S., MacCannell, D. R., Malapati, L., Mathew, S., Mittal, N., Nagilla, R. R., Parikh, R., Paul, P., Rambo-Martin, B.L., Shepard, S.S., Sheth, M., Wentworth, D. E., Winn, A., Hall, A.J., Silk, B.J., Thornburg, N., Kondor, R., Scobie, HM., Paden, C. R., 2023. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023. MMWR Morb Mortal Wkly Rep, 72, 651-656.

  • Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H. H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Caskey, M., Robbiani, D. F., Nussenzweig, M. C., Rice, C. M., Hatziioannou, T., Bieniasz, P. D., 2020. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med, 217, e20201181.

  • Shen, F., Yang, C. X., Lu, Y., Zhang, M., Tian, R. R., Dong, X. Q., Li, A. Q., Zheng, Y. T., Pang, W., 2023. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines. J Med Virol, 95, e28516.

  • Wang, Q., Guo, Y., Zhang, R. M., Ho, J., Mohri, H., Valdez, R., Manthei, D. M., Gordon, A., Liu, L., Ho, D. D., 2023. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect Dis, 23, e397-e398.

  • Yue, C., Song, W., Wang, L., Jian, F., Chen, X., Gao, F., Shen, Z., Wang, Y., Wang, X., Cao, Y., 2023. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect Dis, 23, 278-280.

  • Zhang, L., Kempf, A., Nehlmeier, I., Cossmann, A., Dopfer-Jablonka, A., Stankov, M. V., Schulz, S. R., Jäck, H. M., Behrens, G. M. N., Pöhlmann, S., Hoffmann, M., 2023. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. Lancet Infect Dis, 23, e391-e392.

  • Zhu, A., Wei, P., Man, M., Liu, X., Ji, T., Chen, J., Chen, C., Huo, J., Wang, Y., Zhao, J., 2023. Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2. Signal Transduct Target Ther, 8, 125.